iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/34685677/
The Role of Sodium Glucose Cotransporter-2 Inhibitors in Atherosclerotic Cardiovascular Disease: A Narrative Review of Potential Mechanisms - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 9;10(10):2699.
doi: 10.3390/cells10102699.

The Role of Sodium Glucose Cotransporter-2 Inhibitors in Atherosclerotic Cardiovascular Disease: A Narrative Review of Potential Mechanisms

Jennifer Y Barraclough  1   2 , Sanjay Patel  2   3 , Jie Yu  1 , Bruce Neal  1 , Clare Arnott  1   2   3
Affiliations
Review

The Role of Sodium Glucose Cotransporter-2 Inhibitors in Atherosclerotic Cardiovascular Disease: A Narrative Review of Potential Mechanisms

Jennifer Y Barraclough et al. Cells. .

Abstract

Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of medication with broad cardiovascular benefits in those with type 2 diabetes, chronic kidney disease, and heart failure. These include reductions in major adverse cardiac events and cardiovascular death. The mechanisms that underlie their benefits in atherosclerotic cardiovascular disease (ASCVD) are not well understood, but they extend beyond glucose lowering. This narrative review summarises the ASCVD benefits of SGLT2 inhibitors seen in large human outcome trials, as well as the mechanisms of action explored in rodent and small human studies. Potential pathways include favourable alterations in lipid metabolism, inflammation, and endothelial function. These all require further investigation in large human clinical trials with mechanistic endpoints, to further elucidate the disease modifying benefits of this drug class and those who will benefit most from it.

Keywords: atherosclerosis; cardiovascular disease; inflammation; mechanism of action; sodium glucose cotransporter 2 inhibitor.

PubMed Disclaimer

Conflict of interest statement

J.Y.B. declares no conflict of interest; S.P. declares no conflict of interest; J.Y. declares no conflict of interest.

Figures

Figure 1
Figure 1
Mechanisms of action of SGLT2 inhibitors in atherosclerotic cardiovascular disease; Ach—acetylcholine; hs-CRP—high sensitivity C reactive protein; ICAM—intercellular adhesion molecule; IL—interleukin; NLRP3—NLR family pyrin domain containing 3; CV—cardiovascular, VCAM—vascular cell adhesion molecule; TNF—tumour necrosis factor; TGF—transforming growth factor.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Neal B., Perkovic V., Mahaffey K.W., De Zeeuw D., Fulcher G., Erondu N., Shaw W., Law G., Desai M., Matthews D.R., et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N. Engl. J. Med. 2017;377:644–657. doi: 10.1056/NEJMoa1611925. - DOI - PubMed
    1. Zinman B., Wanner C., Lachin J.M., Fitchett D., Bluhmki E., Hantel S., Mattheus M., Devins T., Johansen O.E., Woerle H.J., et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N. Engl. J. Med. 2015;373:2117–2128. doi: 10.1056/NEJMoa1504720. - DOI - PubMed
    1. Wiviott S.D., Raz I., Bonaca M.P., Mosenzon O., Kato E.T., Cahn A., Trimarco B., Zelniker T.A., Kuder J.F., Murphy S.A., et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2019;380:347–357. doi: 10.1056/NEJMoa1812389. - DOI - PubMed
    1. Perkovic V., Jardine M.J., Neal B., Bompoint S., Heerspink H.J.L., Charytan D.M., Edwards R., Agarwal R., Bakris G., Bull S., et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N. Engl. J. Med. 2019;380:2295–2306. doi: 10.1056/NEJMoa1811744. - DOI - PubMed
    1. Arnott C., Li Q., Kang A., Neuen B.L., Bompoint S., Lam C.S.P., Rodgers A., Mahaffey K.W., Cannon C.P., Perkovic V., et al. Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J. Am. Hear. Assoc. 2020;9:e014908. doi: 10.1161/JAHA.119.014908. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances